C-MYC-miRNA circuitry: A central regulator of aggressive B-cell malignancies

Cell Cycle

Volumn 13, Issue 2, 2014, Pages 191-198

  Tao, Jianguo ^a   Tao, Jiangchuan ^a   Zhao, Xiaohong ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Aggressive B cell lymphomas; C MYC; Epigenetic; Methylation; MiRNA

Indexed keywords

MICRORNA; MYC PROTEIN; ANTINEOPLASTIC AGENT; MYC PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; B CELL LYMPHOMA; CELL INVASION; CELL RENEWAL; CELL SURVIVAL; DOWN REGULATION; DRUG RESISTANCE; FEEDBACK SYSTEM; METABOLISM; PROTEIN EXPRESSION; REGULATORY MECHANISM; ANIMAL; CANCER STEM CELL; GENETICS; HUMAN; LYMPHOMA, B-CELL; MOUSE; PATHOLOGY; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, B-CELL; MICE; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84892615509     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.27646     Document Type: Article

References (63)

1. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006; 16: 318-30; PMID:16934487; http://dx.doi.org/10.1016/j.semcancer.2006.07.015 (Pubitemid 44311040)
2. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008; 22: 2755-66; PMID:18923074; http://dx.doi.org/10.1101/gad.1712408
3. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35; PMID:22464321; http://dx.doi.org/10.1016/j.cell.2012.03.003
4. Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood 2013; 122: 3884-91; PMID:24009228; http://dx.doi.org/10.1182/blood-2013-05-498329
5. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114: 3533-7; PMID:19704118; http://dx.doi.org/10.1182/ blood-2009-05-220095
6. Valera A, López-Guillermo A, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, Espinosa I, Novelli S, Briones J, Mate JL, et al.; Grup per l'Estudi dels Limfomes de Catalunya i Balears (GELCAB). MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 2013; 98: 1554-62; PMID:23716551; http://dx.doi.org/10.3324/ haematol.2013.086173
7. Hernández L, Hernández S, Beà S, Pinyol M, Ferrer A, Bosch F, Nadal A, Fernández PL, Palacín A, Montserrat E, et al. c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin's lymphomas. Leukemia 1999; 13: 2087-93; PMID:10602433; http://dx.doi.org/10.1038/sj.leu.2401599
8. Nagy B, Lundán T, Larramendy ML, Aalto Y, Zhu Y, Niini T, Edgren H, Ferrer A, Vilpo J, Elonen E, et al. Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br J Haematol 2003; 120: 434-41; PMID:12580957; http://dx.doi.org/10.1046/j.1365-2141.2003.04121.x (Pubitemid 36241499)
9. Hartmann E, Fernàndez V, Moreno V, Valls J, Hernández L, Bosch F, Abrisqueta P, Klapper W, Dreyling M, Hoster E, et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol 2008; 26: 4966-72; PMID:18606985; http://dx.doi.org/10.1200/JCO.2007.12.0410
10. Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. Adv Anat Pathol 2011; 18:219-28; PMID:21490439; http://dx.doi.org/10.1097/PAP. 0b013e3182169948
11. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-66; PMID:17060945; http://dx.doi.org/10.1038/nrc1997 (Pubitemid 44629897)
12. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458:762-5; PMID:19219026; http://dx.doi.org/10.1038/nature07823
13. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435:839-43; PMID:15944709; http://dx.doi.org/10.1038/nature03677 (Pubitemid 40839736)
14. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43-50; PMID:18066065; http://dx.doi.org/10.1038/ng.2007.30
15. Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, Bartz SR, Johnson JM, Cummins JM, Raymond CK, Dai H, et al. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol 2007; 27:2240-52; PMID:17242205; http://dx.doi.org/10.1128/MCB.02005-06 (Pubitemid 46418479)
16. Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, Zheng X. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res 2008; 36: 5391-404; PMID:18701644; http://dx.doi.org/10.1093/ nar/gkn522
17. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, Kawamata M, Kelnar K, Bader AG, Brown D, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010; 18:181-7; PMID:19738602; http://dx.doi.org/10.1038/mt.2009.207
18. Wang F, Fu XD, Zhou Y, Zhang Y. Down-regulation of the cyclin E1 oncogene expression by microRNA-16-1 induces cell cycle arrest in human cancer cells. BMB Rep 2009; 42: 725-30; PMID:19944013; http://dx.doi.org/10.5483/BMBRep.2009. 42.11.725
19. Bueno MJ, Malumbres M. MicroRNAs and the cell cycle. Biochim Biophys Acta 2011; 1812:592-601; PMID:21315819; http://dx.doi.org/10.1016/j.bbadis.2011.02. 002
20. Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell 2012; 22: 506-23; PMID:23079660; http://dx.doi.org/10. 1016/j.ccr.2012.09.003
21. Bui TV, Mendell JT. Myc: Maestro of MicroRNAs. Genes Cancer 2010; 1: 568-75; PMID:20882107; http://dx.doi.org/10.1177/1947601910377491
22. Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, Schelter JM, Kobayashi SV, Lim L, Burchard J, Jackson AL, et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 2008; 28:2167-74; PMID:18212054; http://dx.doi.org/10.1128/MCB.01977-07 (Pubitemid 351429964)
23. Kim YK, Yu J, Han TS, Park SY, Namkoong B, Kim DH, Hur K, Yoo MW, Lee HJ, Yang HK, et al. Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res 2009; 37: 1672-81; PMID:19153141; http://dx.doi.org/10.1093/nar/gkp002
24. Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 2010; 17: 215-20; PMID:19498445; http://dx.doi.org/10.1038/cdd.2009.69
25. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26:745-52; PMID:17540599; http://dx.doi.org/10.1016/j.molcel.2007.05. 010 (Pubitemid 46856245)
26. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26:731-43; PMID:17540598; http://dx.doi.org/10.1016/j.molcel.2007.05.017 (Pubitemid 46856247)
27. Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE, Chen-Kiang S, Dalton WS, Sotomayor E, Tao J. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia 2013; 27: 2341-50; PMID:23538750; http://dx.doi.org/10.1038/leu.2013.94
28. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010; 115: 2630-9; PMID:20086245; http://dx.doi.org/10.1182/blood-2009-09-243147
29. Knies-Bamforth UE, Fox SB, Poulsom R, Evan GI, Harris AL. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res 2004; 64: 6563-70; PMID:15374969; http://dx.doi.org/10.1158/0008-5472.CAN-03-3176 (Pubitemid 39297915)
30. Sodir NM, Evan GI. Finding cancer's weakest link. Oncotarget 2011; 2: 1307-13; PMID:22202195
31. El Baroudi M, Corà D, Bosia C, Osella M, Caselle M. A curated database of miRNA mediated feed-forward loops involving MYC as master regulator. PLoS One 2011; 6:e14742; PMID:21390222; http://dx.doi.org/10.1371/journal.pone. 0014742
32. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006; 38: 1060-5; PMID:16878133; http://dx.doi.org/10.1038/ng1855 (Pubitemid 44325933)
33. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009; 15: 6479-83; PMID:19861459; http://dx.doi.org/10.1158/1078-0432.CCR-09-0889
34. Liu W, Le A, Hancock C, Lane AN, Dang CV, Fan TW, Phang JM. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci U S A 2012; 109: 8983-8; PMID:22615405; http://dx.doi.org/10.1073/ pnas.1203244109
35. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20; PMID:18177721; http://dx.doi.org/10.1016/j.cmet.2007.10.002
36. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005; 8:311-21; PMID:16226706; http://dx.doi.org/10.1016/j.ccr.2005.09.008 (Pubitemid 41443416)
37. Lin CH, Jackson AL, Guo J, Linsley PS, Eisenman RN. Myc-regulated microRNAs attenuate embryonic stem cell differentiation. EMBO J 2009; 28:3157-70; PMID:19745813; http://dx.doi.org/10.1038/emboj.2009.254
38. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-72; PMID:18035408; http://dx.doi.org/10.1016/j.cell. 2007.11.019 (Pubitemid 350138099)
39. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007; 448:318-24; PMID:17554336; http://dx.doi.org/10.1038/nature05944 (Pubitemid 47080337)
40. Liu C, Tang DG. MicroRNA regulation of cancer stem cells. Cancer Res 2011; 71: 5950-4; PMID:21917736; http://dx.doi.org/10.1158/0008-5472.CAN-11-1035
41. Rao DS, O'Connell RM, Chaudhuri AA, Garcia- Flores Y, Geiger TL, Baltimore D. MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity 2010; 33: 48-59; PMID:20598588; http://dx.doi.org/10.1016/j.immuni.2010.06.013
42. Craig VJ, Cogliatti SB, Imig J, Renner C, Neuenschwander S, Rehrauer H, Schlapbach R, Dirnhofer S, Tzankov A, Müller A. Mycmediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 2011; 117:6227-36; PMID:21460242; http://dx.doi.org/10.1182/blood-2010-10-312231
43. Peter ME. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 2009; 8: 843-52; PMID:19221491; http://dx.doi.org/10.4161/cc.8.6.7907
44. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP, Krueger LJ. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007; 67: 9762-70; PMID:17942906; http://dx.doi.org/10.1158/0008-5472.CAN-07-2462 (Pubitemid 47621223)
45. Lin J, Lwin T, Zhao JJ, Tam W, Choi YS, Moscinski LC, Dalton WS, Sotomayor EM, Wright KL, Tao J. Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia 2011; 25: 145-52; PMID:20966935; http://dx.doi.org/10.1038/leu.2010.230
46. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603; PMID:19665978; http://dx.doi.org/10.1016/j.cell.2009.07.011
47. Bai JX, Yan B, Zhao ZN, Xiao X, Qin WW, Zhang R, Jia LT, Meng YL, Jin BQ, Fan DM, et al. Tamoxifen represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines. Endocrinology 2013; 154: 635-45; PMID:23295740; http://dx.doi.org/10.1210/en.2012-1607
48. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycombmediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 2010; 39: 761-72; PMID:20832727; http://dx.doi.org/10.1016/j.molcel.2010. 08.013
49. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR- 200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-9; PMID:18483486; http://dx.doi.org/10.1038/embor.2008.74 (Pubitemid 351772923)
50. Lin SL, Chang DC, Chang-Lin S, Lin CH, Wu DT, Chen DT, Ying SY. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 2008; 14: 2115-24; PMID:18755840; http://dx.doi.org/10.1261/rna.1162708
51. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, et al. miR-9, a MYC/MYCNactivated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-56; PMID:20173740
52. Onnis A, De Falco G, Antonicelli G, Onorati M, Bellan C, Sherman O, Sayed S, Leoncini L. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma. PLoS One 2010; 5:5; PMID:20930934; http://dx.doi.org/10.1371/journal.pone. 0012960
53. Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E, et al. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 2012; 31: 3002-8; PMID:22002311; http://dx.doi.org/10.1038/ onc.2011.470
54. Lwin T, Zhao X, Cheng F, Zhang X, Huang A, Shah B, Zhang Y, Moscinski LC, Choi YS, Kozikowski AP, et al. A microenvironment-mediated c-Myc/miR- 548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest 2013; 123:4612-26; PMID:24216476; http://dx.doi.org/10.1172/JCI64210
55. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA. Specific activation of microRNA-127 with downregulation of the protooncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9:435-43; PMID:16766263; http://dx.doi.org/10.1016/j.ccr.2006.04.020 (Pubitemid 43832188)
56. Paik JH, Jang JY, Jeon YK, Kim WY, Kim TM, Heo DS, Kim CW. MicroRNA-146a downregulates NFκB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Clin Cancer Res 2011; 17: 4761-71; PMID:21610143; http://dx.doi.org/10.1158/1078- 0432.CCR-11-0494
57. Chang TC, Zeitels LR, Hwang HW, Chivukula RR, Wentzel EA, Dews M, Jung J, Gao P, Dang CV, Beer MA, et al. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A 2009; 106: 3384-9; PMID:19211792; http://dx.doi.org/10.1073/pnas.0808300106
58. Jiang X, Huang H, Li Z, Li Y, Wang X, Gurbuxani S, Chen P, He C, You D, Zhang S, et al. Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell 2012; 22: 524-35; PMID:23079661; http://dx.doi.org/10.1016/j.ccr.2012.08.028
59. Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ 2013; 20: 1603-14; PMID:24212931; http://dx.doi.org/10.1038/cdd.2013.125
60. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008; 9: 405-14; PMID:18327259; http://dx.doi.org/10.1038/ni1575 (Pubitemid 351405110)
61. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008; 132: 875-86; PMID:18329372; http://dx.doi.org/10.1016/j. cell.2008.02.019 (Pubitemid 351312807)
62. He L, Thomson JM, Hemann MT, Hernando- Monge E, Mu D, Goodson S, Powers S, Cordon- Cardo C, Lowe SW, Hannon GJ, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-33; PMID:15944707; http://dx.doi.org/10.1038/nature03552 (Pubitemid 40839734)
63. Cannell IG, Bushell M. Regulation of Myc by miR- 34c: A mechanism to prevent genomic instability? Cell Cycle 2010; 9: 2726-30; PMID:20603603; http://dx.doi.org/10.4161/cc.9.14.12182